VolitionRx Limited (VNRX) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$4.16M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$5.35M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$5.10M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$6.30M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$4.16M | (m) | (m) | (m) | $1.79K* | -$5.16M* | (m) | $1.80M | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$5.35M | (m) | (m) | (m) | $9.21K | -$5.28M | (m) | $2.85M | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$5.10M | (m) | (m) | (m) | $0.00* | -$3.63M* | (m) | $2.29M | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$6.30M | (m) | (m) | (m) | $76.78K* | -$6.26M* | (m) | $2.72M | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$5.52M | (m) | (m) | (m) | $1.81K | -$4.30M | (m) | $2.61M | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$5.87M | (m) | (m) | (m) | $136.74K* | -$5.39M* | (m) | $3.47M | (m) | (m) |
| 2024-06-30 | Reported | (m) | -$6.99M | (m) | (m) | (m) | $39.35K* | -$6.73M* | (m) | $3.72M | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$8.38M | (m) | (m) | (m) | $28.81K | -$8.34M | (m) | $4.63M | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$8.65M | (m) | (m) | (m) | $273.04K* | -$8.42M* | (m) | $4.65M | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$9.55M | (m) | (m) | (m) | $301.39K* | -$7.35M* | (m) | $5.45M | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$9.05M | (m) | (m) | (m) | $200.59K | -$8.74M | (m) | $4.91M | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$7.99M | (m) | (m) | (m) | $325.49K* | -$6.82M* | (m) | $4.00M | (m) | (m) |
| 2022-06-30 | Reported | (m) | -$8.10M | (m) | (m) | (m) | $541.29K* | -$6.27M* | (m) | $3.28M | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$7.68M | (m) | (m) | (m) | $124.65K | $3.61M | (m) | $3.59M | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$7.56M | (m) | (m) | (m) | $141.81K* | -$4.88M* | (m) | $3.61M | (m) | (m) |
| 2021-06-30 | Reported | (m) | -$5.90M | (m) | (m) | (m) | $219.24K* | -$5.40M* | (m) | $2.94M | (m) | (m) |
| 2021-03-31 | Reported | (m) | -$6.09M | (m) | (m) | (m) | $483.94K | -$6.17M | (m) | $3.87M | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$4.50M | (m) | (m) | (m) | $82.42K* | -$4.50M* | (m) | $3.18M | (m) | $0.00 |
| 2020-06-30 | Reported | (m) | -$5.21M | (m) | (m) | (m) | $266.68K* | -$4.43M* | (m) | $3.49M | (m) | $0.00 |
| 2020-03-31 | Reported | (m) | -$5.87M | (m) | (m) | (m) | $330.69K | -$4.80M | (m) | $3.89M | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$4.18M | (m) | (m) | (m) | $596.33K* | -$3.72M* | (m) | $2.64M | (m) | $0.00 |
| 2019-06-30 | Reported | (m) | -$4.15M | (m) | (m) | (m) | -$124.73K* | -$2.77M* | (m) | $2.48M | (m) | $0.00 |
| 2019-03-31 | Reported | (m) | -$3.99M | (m) | (m) | (m) | -$112.10K | -$3.65M | (m) | $2.47M | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$4.45M | (m) | (m) | (m) | -$58.03K* | -$4.61M* | (m) | $2.74M | (m) | (m) |
| 2018-06-30 | Reported | (m) | -$4.57M | (m) | (m) | (m) | -$186.17K* | -$2.98M* | (m) | $2.69M | (m) | (m) |
| 2018-03-31 | Reported | (m) | -$4.63M | (m) | (m) | (m) | $60.66K | -$3.51M | (m) | $2.42M | (m) | (m) |
| 2017-09-30 | Reported | (m) | -$3.88M | (m) | (m) | (m) | $105.34K* | -$2.82M* | (m) | $2.13M | (m) | (m) |
| 2017-06-30 | Reported | (m) | -$3.44M | (m) | (m) | (m) | $360.00K* | -$2.81M* | (m) | $1.81M | (m) | (m) |
| 2017-03-31 | Reported | (m) | -$3.34M | (m) | (m) | (m) | $874.89K | -$2.67M | (m) | $1.67M | (m) | (m) |
| 2016-09-30 | Reported | (m) | -$3.48M | (m) | (m) | (m) | $21.05K* | -$2.11M* | (m) | $1.97M | (m) | (m) |
| 2016-06-30 | Reported | (m) | -$2.98M | (m) | (m) | (m) | (m) | -$2.40M* | (m) | $1.75M | (m) | (m) |
| 2016-03-31 | Reported | (m) | -$2.49M | (m) | (m) | (m) | (m) | -$2.16M | (m) | $1.46M | (m) | (m) |
| 2015-09-30 | Reported | (m) | -$2.97M | (m) | (m) | (m) | $5.64K* | -$2.34M* | (m) | $1.86M | (m) | $4.60K |
| 2015-06-30 | Reported | (m) | -$2.02M | (m) | (m) | (m) | $43.95K* | -$1.93M* | (m) | $1.36M | (m) | (m) |
| 2015-03-31 | Reported | (m) | -$2.35M | (m) | (m) | (m) | $18.30K | -$2.21M | (m) | $1.21M | (m) | (m) |
| 2014-09-30 | Reported | (m) | -$1.76M | (m) | (m) | (m) | $250.94K* | -$863.60K* | (m) | $1.07M | (m) | (m) |
| 2014-06-30 | Reported | (m) | -$1.05M | (m) | (m) | (m) | $28.60K* | -$1.31M* | (m) | $791.29K | (m) | (m) |
| 2014-03-31 | Reported | (m) | -$1.24M | (m) | (m) | (m) | $18.07K | -$977.56K | (m) | $870.46K | (m) | (m) |
| 2013-09-30 | Reported | (m) | -$925.57K | (m) | (m) | (m) | -$1.00* | -$827.84K* | (m) | $524.53K | (m) | (m) |
| 2013-06-30 | Reported | (m) | -$1.05M | (m) | (m) | (m) | $0.00* | -$990.75K* | (m) | $640.64K | (m) | (m) |
| 2013-03-31 | Reported | (m) | -$907.80K | (m) | (m) | (m) | $714.00 | -$556.35K | (m) | $593.20K | (m) | (m) |
| 2012-09-30 | Reported | (m) | -$872.52K | (m) | (m) | (m) | $455.00* | -$723.53K* | (m) | $633.80K | (m) | (m) |
| 2012-06-30 | Reported | (m) | -$931.47K | (m) | (m) | (m) | $33.33K* | -$579.67K* | (m) | $559.43K | (m) | (m) |
| 2012-03-31 | Reported | (m) | -$801.74K | (m) | (m) | (m) | $37.80K | -$564.08K | (m) | $511.05K | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$21.74M | (m) | (m) | (m) | $89.56K | -$19.68M | (m) | $10.08M | (m) | (m) |
| 2024-12-31 | Reported | (m) | -$27.02M | (m) | (m) | (m) | $277.50K | -$25.89M | (m) | $14.41M | (m) | (m) |
| 2023-12-31 | Reported | (m) | -$35.99M | (m) | (m) | (m) | $1.08M | -$18.06M | (m) | $19.55M | (m) | (m) |
| 2022-12-31 | Reported | (m) | -$31.78M | (m) | (m) | (m) | $1.57M | -$15.28M | (m) | $15.33M | (m) | (m) |
| 2021-12-31 | Reported | (m) | -$28.33M | (m) | (m) | (m) | $973.56K | -$20.85M | (m) | $13.02M | (m) | (m) |
| 2020-12-31 | Reported | (m) | -$21.25M | (m) | (m) | (m) | $1.94M | -$16.46M | (m) | $14.53M | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$16.04M | (m) | (m) | (m) | $511.27K | -$12.74M | (m) | $10.36M | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$17.90M | (m) | (m) | (m) | -$301.81K | -$14.73M | (m) | $10.91M | (m) | (m) |
| 2017-12-31 | Reported | (m) | -$14.70M | (m) | (m) | (m) | $1.43M | -$12.19M | (m) | $8.03M | (m) | (m) |
| 2016-12-31 | Reported | (m) | -$12.43M | (m) | (m) | (m) | $415.09K | -$8.86M | (m) | $7.90M | (m) | (m) |
| 2015-12-31 | Reported | (m) | -$10.01M | (m) | (m) | (m) | $77.19K | -$8.55M | (m) | $6.10M | (m) | -$4.60K |
| 2014-12-31 | Reported | (m) | -$5.95M | (m) | (m) | (m) | $302.99K | -$4.14M | (m) | $4.04M | (m) | (m) |
| 2013-12-31 | Reported | (m) | -$4.58M | (m) | (m) | (m) | $714.00 | -$3.08M | (m) | $2.50M | (m) | (m) |
| 2012-12-31 | Reported | (m) | -$4.08M | (m) | (m) | (m) | $90.69K | -$2.31M | (m) | $2.77M | (m) | (m) |
| 2011-12-31 | Reported | (m) | -$2.61M | (m) | (m) | (m) | $34.87K | -$1.65M | (m) | $1.52M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |